J Pediatr Intensive Care
DOI: 10.1055/s-0042-1760297
Original Article

Methylene Blue Use in Pediatrics

Rachel Moss 
1   Division of Critical Care Medicine, Department of Pediatrics, Mount Sinai Kravis Children's Hospital, New York, New York, United States
,
Kim R. Derespina
1   Division of Critical Care Medicine, Department of Pediatrics, Mount Sinai Kravis Children's Hospital, New York, New York, United States
,
Jessica Frye
2   Department of Pharmacy, Mount Sinai Hospital, New York, New York, United States
,
Shubhi Kaushik
1   Division of Critical Care Medicine, Department of Pediatrics, Mount Sinai Kravis Children's Hospital, New York, New York, United States
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Catecholamine-resistant shock, also known as vasoplegia, is a challenging entity with a significant risk of mortality. We seek to provide further data on the safety and effectiveness of methylene blue (MB) for vasoplegic shock in the pediatric population. We conducted a retrospective observational study of pediatric patients admitted to the pediatric intensive care unit or pediatric cardiac intensive care unit at Mount Sinai Kravis Children's Hospital from 2011 to 2021 who received MB for refractory shock. A list of patients was obtained by performing a pharmaceutical query from 2011 to 2021 for “MB.” Chart review was performed to determine indication for use and to collect demographic and clinical data. There were 33 MB administrations: 18 administrations (16 unique patients) for vasoplegic shock, 11 for surgical dye, and 4 for methemoglobinemia. The median age was 5 years (interquartile range [IQR]: 0.08, 13). Ten patients required MB following congenital cardiac repair (62.5%); one administration for myocarditis, septic shock, postcardiac arrest, high output chylothorax, scoliosis repair, and one multisystem inflammatory syndrome in children. No patients experienced hemolytic anemia or serotonin syndrome following administration. The median dose of MB was 1 mg/kg. Vasoactive-inotrope score (VIS) improved in 4 out of 18 administrations at 1 hour. Mean arterial pressure (MAP) improved in 10 out of 18 administrations at 1 hour. Systolic blood pressure (SBP) improved in 8 out of 18 administrations at 1 hour. VIS, MAP, and SBP improved in 8 out of 18 administrations at 6 hours. MB may be safely considered as rescue therapy in catecholamine-resistant shock in pediatrics.

Keywords

vasoplegic shock - methylene blue - vasoplegia - pediatrics


Publication History

Received: 16 September 2022

Accepted: 23 November 2022

Article published online:
05 January 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Ginimuge PR, Jyothi SD. Methylene blue: revisited. J Anaesthesiol Clin Pharmacol 2010; 26 (04) 517-520
    CrossrefPubMedGoogle Scholar
  • 2 Pasin L, Umbrello M, Greco T. et al. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Crit Care Resusc 2013; 15 (01) 42-48
    PubMedGoogle Scholar
  • 3 Zhang X, Gao Y, Pan P, Wang Y, Li W, Yu X. [Methylene blue in the treatment of vasodilatory shock: a meta-analysis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2017; 29 (11) 982-987
    PubMedGoogle Scholar
  • 4 Otero Luna AV, Johnson R, Funaro M, Canarie MF, Pierce RW. Methylene blue for refractory shock in children: a systematic review and survey practice analysis. Pediatr Crit Care Med 2020; 21 (06) e378-e386
    CrossrefPubMedGoogle Scholar
  • 5 Morin L, Ray S, Wilson C. et al; ESPNIC Refractory Septic Shock Definition Taskforce the Infection Systemic Inflammation Sepsis section of ESPNIC. Refractory septic shock in children: a European Society of Paediatric and Neonatal Intensive Care definition. Intensive Care Med 2016; 42 (12) 1948-1957
    CrossrefPubMedGoogle Scholar
  • 6 Gaies MG, Jeffries HE, Niebler RA. et al. Vasoactive-inotropic score is associated with outcome after infant cardiac surgery: an analysis from the Pediatric Cardiac Critical Care Consortium and Virtual PICU System Registries. Pediatr Crit Care Med 2014; 15 (06) 529-537
    CrossrefPubMedGoogle Scholar
  • 7 Hassan G, Salem Y, Labib H, Elmidany A. Methylene blue for the management of pediatric patients with vasoplegic syndrome. Original Article. Egypt J Cardiothorac Anesth 2014; 8 (02) 66-74
    CrossrefPubMedGoogle Scholar
  • 8 Abdelazim R, Salah D, Labib HA, El Midany AA. Methylene blue compared to norepinephrine in the management of vasoplegic syndrome in pediatric patients after cardiopulmonary bypass: a randomized controlled study. Egypt J Anaesth 2016; 32 (03) 269-275
    CrossrefPubMedGoogle Scholar
  • 9 Scheffer AL, Willyerd FA, Murk AL. et al. Methylene blue treatment of pediatric patients in the cardiovascular intensive care unit. Southwest J Pulm Crit Care 2021; 23 (01) 8-17
    CrossrefPubMedGoogle Scholar
  • 10 Mehaffey JH, Johnston LE, Hawkins RB. et al. Methylene blue for vasoplegic syndrome after cardiac operation: early administration improves survival. Ann Thorac Surg 2017; 104 (01) 36-41
    CrossrefPubMedGoogle Scholar
  • 11 Oberpaur B, Donoso A, Claveria C. et al. Azul de metileno en niños con hipotensión refractaria por choque séptico. Rev Chil Pediatr 1997; 68 (05) 205–209
    CrossrefPubMedGoogle Scholar
  • 12 Weiner MM, Lin HM, Danforth D, Rao S, Hosseinian L, Fischer GW. Methylene blue is associated with poor outcomes in vasoplegic shock. J Cardiothorac Vasc Anesth 2013; 27 (06) 1233-1238
    CrossrefPubMedGoogle Scholar
  • 13 Evora PR, Roselino CH, Schiaveto PM. Methylene blue in anaphylactic shock. Ann Emerg Med 1997; 30 (02) 240
    CrossrefPubMedGoogle Scholar
  • 14 Driscoll W, Thurin S, Carrion V, Steinhorn RH, Morin III FC. Effect of methylene blue on refractory neonatal hypotension. J Pediatr 1996; 129 (06) 904-908
    CrossrefPubMedGoogle Scholar
  • 15 Puntillo F, Giglio M, Pasqualucci A, Brienza N, Paladini A, Varrassi G. Vasopressor-sparing action of methylene blue in severe sepsis and shock: a narrative review. Adv Ther 2020; 37 (09) 3692-3706
    CrossrefPubMedGoogle Scholar
  • 16 Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care 2002; 30 (06) 755-762
    CrossrefPubMedGoogle Scholar
  • 17 Weingartner R, Oliveira E, Oliveira ES. et al. Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue. Braz J Med Biol Res 1999; 32 (12) 1505-1513
    CrossrefPubMedGoogle Scholar
  • 18 George M. Methylene-blue-induced hyperbilirubinemia and phototoxicity in a neonate. Clin Pediatr (Phila) 2000; 39 (11) 659-661
    CrossrefPubMedGoogle Scholar
  • 19 Chan BS, Becker T, Chiew AL. et al. Vasoplegic shock treated with methylene blue complicated by severe serotonin syndrome. J Med Toxicol 2018; 14 (01) 100-103
    CrossrefPubMedGoogle Scholar
  • 20 Kirov MY, Evgenov OV, Evgenov NV. et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med 2001; 29 (10) 1860-1867
    CrossrefPubMedGoogle Scholar
  • 21 Brown G, Frankl D, Phang T. Continuous infusion of methylene blue for septic shock. Postgrad Med J 1996; 72 (852) 612-614
    CrossrefPubMedGoogle Scholar
  • 22 Sills MR, Zinkham WH. Methylene blue-induced Heinz body hemolytic anemia. Arch Pediatr Adolesc Med 1994; 148 (03) 306-310
    CrossrefPubMedGoogle Scholar
  • 23 Vanhinsbergh L, Uthaya S, Bain BJ. Methylene blue-induced Heinz body hemolytic anemia in a premature neonate. Am J Hematol 2018; 93 (05) 716-717
    CrossrefPubMedGoogle Scholar
  • 24 Sikka P, Bindra VK, Kapoor S, Jain V, Saxena KK. Blue cures blue but be cautious. J Pharm Bioallied Sci 2011; 3 (04) 543-545
    CrossrefPubMedGoogle Scholar
  • 25 Datt V, Wadhhwa R, Sharma V, Virmani S, Minhas HS, Malik S. Vasoplegic syndrome after cardiovascular surgery: a review of pathophysiology and outcome-oriented therapeutic management. J Card Surg 2021; 36 (10) 3749-3760
    CrossrefPubMedGoogle Scholar
  • 26 McIntosh AM, Tong S, Deakyne SJ, Davidson JA, Scott HF. Validation of the vasoactive-inotropic score in pediatric sepsis. Pediatr Crit Care Med 2017; 18 (08) 750-757
    CrossrefPubMedGoogle Scholar